Scientists Develop Human Antibodies to Combat Black Widow Spider Venom

New research aims to replace horse-derived antivenoms with lab-generated human antibodies to reduce allergic reactions and improve effectiveness.

Researchers identified 45 human antibodies capable of neutralizing alpha-latrotoxin, the venom of the European black widow spider.
The standout antibody, MRU44-4-A1, showed high effectiveness in lab tests.
Current antivenoms are derived from horses and can cause serious allergic reactions in some patients.
Human-derived antibodies could provide a safer, more consistent treatment for black widow spider bites.
Further testing and development are needed before the new antivenom can be used in clinical settings.